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http:WHAT THIS PAPER ADDS
Endovenous laser ablation (EVLA) of the saphenous vein has been performed for over 10 years with increasing
acceptance. However, the effect of EVLA in patients with incompetent perforating veins (IPVs) remains unclear.
In this study, EVLA is shown to be safe and effective in ablating IPVs in patients with venous insufﬁciency. Apart
from this, no improvement of clinical score, ulcer healing, or varicose vein recurrence has been found as a result
of the additional IPV EVLA at 1 year follow up.Objective/Background: This study aimed to investigate the clinical results and fate of incompetent perforating
veins (IPVs) following treatment of superﬁcial venous insufﬁciency, with or without endovenous laser ablation
(EVLA) of IPVs.
Methods: A retrospective analysis of patients with primary venous insufﬁciency (PVI) was conducted in a single
institution from January, 2010 to December, 2011. IPVs were found in 311 patients (376 limbs). Among these, 132
patients (156 limbs) were treated with EVLA of IPVs and varicose vein surgery, and the remaining 179 patients
(220 limbs) were treated with varicose vein surgery alone and served as controls. The fate of the IPVs,
complications and clinical results were evaluated.
Results: The technical success rate of EVLA of IPVs was 100%. There was no statistical difference in complications
between the two groups. At 1 year follow up, 68 perforators were recanalized and still incompetent in the EVLA
treated IPV group compared with 437 incompetent perforators in the untreated IPV group (18.7% vs. 92.6%;
p < .001). A faster median ulcer healing time (1.40 months) was found in the EVLA treated IPV group (95%
conﬁdence interval [CI] 1.15e1.66 vs. 3.30 months [95% CI 2.50e4.10]; p ¼ .001), even though no statistical
difference in the 12 month ulcer healing rate was observed between the two groups (p ¼ .584). There were no
signiﬁcant differences between the two groups for varicose vein recurrence rates or changes in the Venous
Clinical Severity Score (VCSS).
Conclusion: EVLA was safe and effective in reducing the number of IPVs in PVI. However, the addition of IPV EVLA
had no effect on ulcer healing rate, VCSS or varicose vein recurrence at 1 year follow up.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In recent years, endovenous laser ablation (EVLA) therapies
have been recommended over high ligation and stripping as
the ﬁrst line treatment of choice for varicose veins
associated with axial reﬂux by the Joint Committee of the
Society for Vascular Surgery/American Venous Forum.1
While evidence of fewer complications, faster recovery
times, and improved short-term results for EVLA treatment
of superﬁcial venous insufﬁciency (SVI) has consistently
increased,2e4 the role of EVLA in treating incompetentresponding author.
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//dx.doi.org/10.1016/j.ejvs.2015.01.013perforating veins (IPVs) combined with SVI has not yet been
deﬁned.1,5,6
The reasons can be summarized as follows. First, the
hemodynamic impact of IPVs on primary venous
insufﬁciency (PVI) has been controversial. Some studies
have suggested that the interruption of IPVs could improve
ulcer healing and reduce recurrence.7e9 However, others
reported that pre-emptive intervention to IPVs was not
associated with any clinical beneﬁt,10,11 and that, on
average, 50% of IPVs regained competency following
standard varicose vein surgery.12,13 Second, most IPV
interruptions were performed with ablation of the SVI.
Thus, any beneﬁt directly attributable to the interruption of
IPVs is not clearly deﬁned in the absence of a control
group.1 Last, as a new technique for the treatment of IPVs,
the majority of studies published on perforator EVLA have
Effect of Endovenous Laser Ablation 575reported small numbers of patients, short-term follow ups,
and a lack of both clinical and functional results.6,14e17
The aim of this retrospective study was to assess the fate
of IPVs after varicose vein treatment, with and without
EVLA for IPVs. Secondary outcome measures included
complications, ulcer healing rates, varicose vein recurrence
rates, and the Venous Clinical Severity Score (VCSS) over a
12 month follow up period.METHODS
Study group
Institutional review board approval was obtained for this
study. The study comprised a retrospective review of a
prospectively maintained venous database at Shanghai
Ninth People’s Hospital, extending from January 2010 to
December 2011. Patients with lower limb varicose veins
were examined by Doppler ultrasound and selective phle-
bography. Doppler ultrasound was performed in the upright
position and with manual compression to assist in the
identiﬁcation of IPVs. Superﬁcial veins (including the great
and small saphenous veins), deep veins (including the
femoral and popliteal veins), and perforating veins in the
medial calf were examined. Reﬂux was deﬁned as ﬂow
retrograde to the direction of physiological ﬂow and lasting
for >0.5 seconds. Phlebography was selectively used in
cases with exercise induced pain or edema to exclude post-
thrombotic syndrome and MayeThurner syndrome, both
conditions that could be missed by ultrasonography.
Patients suffering from great saphenous vein (GSV) and
perforating vein insufﬁciency, with or without deep venous
insufﬁciency (DVI), were admitted to the study. Exclusion
criteria included former varicose vein surgery, vascular
malformation, post-thrombotic syndrome, MayeThurner
syndrome, venous obstructive disease, telangiectasia (CEAP
classiﬁcation C1), and an ankleebrachial index <0.9. In
addition, in order to avoid confounding the data, patients
diagnosed with concomitant small saphenous vein insufﬁ-
ciency or non-medial calf ulcers were excluded. De-
mographic data on age, sex, body mass index (BMI),
number and diameter of IPVs and ulcers, and comorbidities
were collected.Procedure
Doppler ultrasound scanning (Acuson CV70; Siemens Med-
ical Solutions USA, Inc., Malvern, PA, USA) was performed in
the upright position by a single experienced sonographer
prior to treatment. Perforating veins were identiﬁed by
cross sectional scanning in real time B-mode, starting from
the medial malleolus and extending up to the knee. Once
the target vein was located, the probe was rotated vertically
in order to capture the full perforating vein length, from its
most superﬁcial point extending to the deepest point below
the muscle fascia. IPVs were conﬁrmed if an outward ﬂow
exceeding 0.5 seconds in duration was documented using a
manual limb compressionedecompression maneuver. IPVswere marked on the skin at the point where they met the
superﬁcial vein.
Patient consent was obtained prior to treatment. EVLA
was performed with a 810 nm diode laser generator
(Diomed Limited, Cambridge, UK) coupled to a 600 mm bare
tipped ﬁber. In order to avoid the squeeze and spasm of
IPVs caused by tumescent anesthesia, intravenous anes-
thesia or laryngeal mask anesthesia was chosen in all pa-
tients. Marked IPVs were accessed by duplex guided
puncture above the fascial plane with an 18 gauge
(1,320 nm) cannula. After removal of the delivery needle,
the ﬁber catheter was advanced at least 1 cm from the
deep vein system under B-mode scan. Laser power was
generally set to between 12 and 14 W. Energy was
administrated in a pulsed fashion at approximately 100 J/cm
to the treated vein. Doppler ultrasound was used to conﬁrm
occlusion of the treated vein segment and the patency of
nearby deep veins after EVLA (Fig. 1). In case of residual
ﬂow in the IPVs, the treatment procedure was repeated
instantly. EVLA treatment for GSV and tributary varicose
veins was performed in all patients in accordance with a
four step protocol as previously described.18,19 First, high
ligation of the GSV was used to decrease the risk of
thrombus in the femoral vein and GSV recanalization caused
by saphenofemoral junction reﬂux, and to facilitate
thrombosis and ﬁbrosis throughout the GSV. Second, the
GSV was cannulated at the ankle level with Seldinger
technique. Third, the varicose branches were cannulated
with 18 gauge needles or 5-F introducer dilators segmen-
tally, followed by laser ablation. Finally, GSV laser ablation
was performed via the ankle level cannula.
After treatment an elastic compression bandage was
applied across the whole lower limb. Patients were given
direction regarding activity levels, pain control, and the use
of the compression stocking. A grade II compression
stocking was recommended to be worn continuously for an
initial period of 1 week and for up to 12 weeks during active
periods.
Follow up
Follow up was at 1, 3, 6, and 12 months. Treatment related
complications were recorded after EVLA. The fate of IPVs
along the medial calf both with and without perforator
ablation, and the patency of lower limb deep veins were
evaluated using Doppler ultrasound. In order to evaluate
clinical outcomes, VCSS, median ulcer healing time, ulcer
healing rate, and the varicose vein recurrent rate of treated
legs were recorded at the above mentioned follow up
points. Ulcer healing was deﬁned as complete epithelial-
ization. Varicose vein recurrence was deﬁned as the
appearance of new varices not observed before treatment
or re-appearance of varices where they had been elimi-
nated at surgery.
Statistical analysis
Individual data were summarized using frequencies or
percentages for categorical variables, the mean  SD for
Table 1. Procedures and laser energy.
Variable EVLA treated
IPV group
Untreated
IPV group
Patients (n) 132 179
Limbs (n) 156 220
EVLA (GSV þ tributaries), n (%) 95 (60.9) 127 (57.7)
EVLA þ stripping, n (%) 22 (14.1) 47 (21.4)
EVLA þ ulcer debridement, n (%) 39 (25.0) 46 (20.9)
Laser energy for
perforating veins, J (range)
205 (63e392) NA
Total laser energy, J (range) 1679
(879e2,498)
1,511
(737e2,564)
Note. EVLA ¼ endovenous laser ablation; GSV ¼ great saphenous
vein; NA ¼ not applicable.
Figure 1. Endovenous laser ablation procedure of an incompetent perforating vein (IPV) of the leg under intra-operative duplex exami-
nation. (A) The colored signal shows an IPV ﬂow (white arrow) from the deep vein to the superﬁcial vein. (B) Percutaneous cannula (white
arrow) was advanced and accessed the IPV under ultrasound guidance. (C) Post-operative duplex examination of an occluded IPV.
Associated deep vein can be seen without thrombosis. (D) Schematic drawing of IPV cannulation with ultrasound guidance.
576 H. Shi et al.normally distributed continuous variables, and median
(range) for non-normal values. SPSS version 13.0 (IBM,
Armonk, NY, USA) was used for statistical analysis. Median
ulcer healing times were calculated using KaplaneMeier
estimation. The rate of complications, ulcer healing, and
varicose vein recurrence, and the proportion of post-
operative IPVs was tested using Fisher’s exact test. An
analysis of variance was used to compare outcomes
regarding VCSS. A p-value < .050 was considered statisti-
cally signiﬁcant.
RESULTS
Patient characteristics
Of the 331 patients (376 limbs) with IPVs, 132 (156 limbs)
had their IPVs treated with EVLA by three experienced
surgeons; the remaining 179 (220 limbs) were not treated
for IPVs. All patients received EVLA for both the GSV and
tributaries. Combined therapies, including segmental strip-
ping of large varicose veins that could not be ablated by
laser and ulcer debridement, are shown in Table 1. Mean
age, male to female ratio, and BMI did not differ between
the EVLA treated IPV group and the untreated IPV group.
No difference was observed between the two groups with
regard to the mean diameter of IPVs and the median
diameter of ulcers (Table 2).
In both groups the clinical presentation spanned the
spectrum of the CEAP classiﬁcation (Table 3). No difference
was observed in pre-operative CEAP classiﬁcation orpositive ulcer bacterial culture rate between the two
groups. The distribution of combined DVI between the two
groups also showed no signiﬁcant difference (p ¼ .199)
(Table 3). Although an additional 205 J (range 63e392 J)
was required to ablate the IPVs in the EVLA treated IPV
group, there was no signiﬁcant difference in the total laser
energy used between the groups (p ¼ .788).
Clinical results
EVLA was technically successful in all cases of IPV ablation,
although repeat access and laser ablation was performed
simultaneously in 26 limbs in which residual ﬂow was
observed after ﬁrst access. There was no operative mortality
Table 2. Demographic characteristics of patients.
Variable EVLA treated
IPV group
Untreated
IPV group
Mean age, y (range) 60.7
(41.0e75.0)
58.3
(38.0e79.0)
Sex (male:female) 53:79 64:115
BMI (range) 24.7
(17.6e32.9)
23.9
(19.2e34.5)
Patients (n) 132 179
Limbs (n) 156 220
IPVs (n) 363 472
Mean diameter of IPVs,
mm (range)a
3.4
(1.8e5.9)
3.2
(1.6e6.2)
Ulcerations (n) 43 49
Median diameter of
ulceration, mm (range)
3.3
(1.0e6.5)
3.9
(1.5e10.0)
Diabetes mellitus (%) 28 (21.2) 26 (14.5)
Hyperlipidemia (%) 25 (18.9) 31 (17.3)
Hypertension (%) 34 (25.8) 41 (22.9)
Superﬁcial thrombophlebitis (%) 16 (10.3) 28 (12.7)
Note. EVLA ¼ endovenous laser ablation; IPV ¼ incompetent
perforating vein; BMI ¼ body mass index.
a Measured in the upright position.
Table 4. Complications after treatment (number of limbs).
Complications EVLA treated
IPV group
Untreated
IPV group
p
Total limbs (n) 156 220
Ecchymosis and induration 107 (68.6) 132 (60.0) .088
Pain (requiring oral
medication)
21 (13.5) 18 (8.2) .098
Paresthesia 18 (10.8) 14 (6.4) .114
Phlebitis 18 (11.5) 23 (10.5) .740
Calf deep vein
thrombosis
3 (1.9) 1 (0.5) .171
Skin necrosis 2 (1.3) 1 (0.5) .374
Note. Values are given as n (%) unless otherwise indicated.
EVLA ¼ endovenous laser ablation; IPV ¼ incompetent
perforating vein.
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differ statistically between the EVLA treated IPV group and
the untreated IPV group (Table 4). Ecchymosis and indura-
tion were the most common complications in both groups
(68.6% vs. 60.0%), but these resolved within 2e4 weeks.
Pain (requiring oral medication), paresthesia, and phlebitis
occurred in both groups with an incidence of 6.4% to 13.5%,
respectively. Calf deep vein thrombosis (DVT) and skin ne-
crosis were rare. Four patients with calf DVT received low
molecular weight heparin at a dose of 4,000 U/day for 2
weeks, resulting in no residual thrombosis. Three patients
with skin necrosis were completely healed at the 1 month
follow up.Table 3. CEAP classiﬁcation and venous reﬂux.
Variable EVLA treated
IPV group
Untreated
IPV group
Total limbs (n) 156 220
C1 0 (0) 0 (0)
C2 14 (9.0) 30 (13.6)
C3 30 (19.2) 43 (19.5)
C4 39 (25.0) 41 (18.6)
C5 30 (19.2) 57 (25.9)
C6 43 (27.6) 49 (22.3)
C6 ulcer bacterial
culture positive
20 (46.5) 27 (55.1)
IPVs þ ISVs 101 (64.7) 128 (58.2)
IPVs þ ISVs þ IDVs 55 (35.3) 92 (41.8)
Note. Values are given as n (%) unless otherwise indicated.
EVLA ¼ endovenous laser ablation; IPV ¼ incompetent
perforating vein; ISV ¼ incompetent superﬁcial vein;
IDV ¼ incompetent deep vein.96.1% of patients were followed up at 1 year, including
four patients absent from the EVLA treated IPV group,
seven who were absent from the untreated IPV group, and
one non-EVLA related death in the untreated IPV group. The
results for the perforating veins are summarized in Table 5.
Sixty-eight perforators were recanalized and still incompe-
tent in the EVLA treated IPV group compared with 437
incompetent perforators in the untreated IPV group (18.7%
vs. 92.6%; p < .001). There was no statistical difference in
the rate of recanalization between the different CEAP clin-
ical classiﬁcations in the EVLA treated IPV group. However,
patients with C2 and C3 symptoms demonstrated a signif-
icant decrease in IPVs compared with C4, C5, and C6 pa-
tients in the untreated IPV group after EVLA (Table 5).
At the 1 year follow up, 40/43 (93.0%) ulcers in the EVLA
treated IPV group and 44/49 (89.8%) ulcers in the untreated
IPV group had healed completely. Although no statistical
difference in ulcer healing rate was observed between the
two groups (p ¼ .584), KaplaneMeier analysis revealed
signiﬁcant changes in median ulcer healing time between
the EVLA treated IPV group and the untreated IPV group
(1.40 months [95% conﬁdence interval {CI} 1.15e1.66 vs.
3.30 months [95% CI 2.50e4.10]; p ¼ .001) (Fig. 2). The
varicose vein recurrence rate at 6 and 12 months showed
no statistical difference between the EVLA treated IPV
group and the untreated IPV group (2.56% vs. 3.64%
[p ¼ .560]; 5.13% vs. 7.27% [p ¼ .402]). VCSS at the 1, 3, 6,
and 12 month follow ups also demonstrated no difference
between the two groups [5.03  3.00 vs. 5.72  3.42
[p ¼ .344]; 2.86  2.12 vs. 3.26  2.84 [p ¼ .486];
2.09  1.70 vs. 2.38  1.98 [p ¼ .494], and 1.69  1.63 vs.
1.72  1.58 [p ¼ .934], respectively).
DISCUSSION
Although subfascial endoscopic perforator surgery (SEPS)
has been the most common treatment for IPVs, ultrasound
guided EVLA may have several potential advantages over
this method. First, EVLA is not limited by perforator loca-
tion, and can include those close to the medial malleolus
with chronic inﬂammatory ﬁbrosis and that are difﬁcult to
access by SEPS. Second, a high technical success rate is
achieved by IPV EVLA.15,20 All perforators in this study were
Table 5. Results of perforating veins using Doppler ultrasound at 1 year follow up.
CEAP classiﬁcation No. of IPVs (EVLA treated IPV group) No. of IPVs (untreated IPV group)
Pre-treatment Post-treatment Pre-treatment Post-treatment
C2 (%) 21 2 (9.5)a 36 25 (69.4)b
C3 (%) 70 9 (12.9)a 67 54 (80.6)b
C4 (%) 67 14 (20.9)a 75 71 (94.7)
C5 (%) 87 20 (23.0)a 153 151 (98.7)
C6 (%) 118 23 (19.5)a 141 136 (96.5)
Total 363 68 (18.7)a 472 437 (92.6)
Note. IPV ¼ incompetent perforating vein; EVLA ¼ endovenous laser ablation.
a p < .010 compared with corresponding data in the untreated IPV group.
b p < .050 compared with C4, C5, and C6 in the untreated IPV group.
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current study, multi-access and ablation of IPVs with re-
sidual ﬂow and simultaneous treatment of inﬂow SVI are
the key indicators of a high success rate. Third, EVLA is a
much less invasive treatment, with few procedure related
complications.1,20 Three (1.9%) calf DVTs and two (1.3%)
incidences of skin necrosis occurred in the IPV treated
group, which might have been due to the close proximity
between laser tip and the deep vein (<1 cm), a very su-
perﬁcial varicose vein without tumescent anesthesia, and
high cumulative energy at the same point (>200 J). Despite
this, the complications seen in the EVLA treated IPV group
were not signiﬁcantly different compared with the un-
treated IPV group.
At the 1 year follow up, recanalization was found in 68
perforators (18.7%), which were still incompetent in the
EVLA treated IPV group. Although higher rates of IPV
occurrence were detected with more serious CEAP classiﬁ-
cation before EVLA, there was no statistical difference in the
rate of recanalization between different CEAP classiﬁcations
after EVLA. More than 90% of IPVs in the untreated IPVFigure 2. KaplaneMeier analysis of ulcer healing during 1 year of
follow up. Note. EVLA ¼ endovenous laser ablation;
IPV ¼ incompetent perforating vein.group were still incompetent at the 1 year follow up.
Interestingly, patients with C2 and C3 symptoms demon-
strated a statistically lower incidence of IPVs compared with
C4, C5, and C6 after superﬁcial vein EVLA. It may be spec-
ulated that, although EVLA is easy and efﬁcient at ablating
the IPVs of C2 and C3 patients, compared with C4eC6 pa-
tients, signiﬁcant IPV reversal can be achieved with super-
ﬁcial vein EVLA alone.
At present, there is no compelling level 1 evidence to
support a grade A recommendation that the treatment of
IPVs affects venous ulcer healing or recurrence.21,22 How-
ever, a number of studies have shown the clinical efﬁcacy of
IPV interruption in decreasing the symptoms of PVI and
rapidly healing ulcers.23e26 Nelzén and Fransson reported
the long-term healing and recurrence of venous leg ulcers
following SEPS combined with superﬁcial venous surgery.25
Half of the legs were healed within 2 months, and the 42
month cumulative healing rate was 87%. The 3 and 5 year
recurrence rates were 8% and 18%, respectively.25 In this
study, although a signiﬁcant decrease in median ulcer
healing time was noted in the EVLA treated IPV group, the
ulcer healing rate of both groups eventually reached the
same point at the 1 year follow up. Ulcer recurrence was
not detected in either group, partially owing to the limita-
tion of the 1 year follow up, but also as a result of the
extended recommended time for compression stocking use
in ulceration patients. Results for VCSS showed no statistical
difference between the two groups at different time points.
While most clinicians agree that the incompetent perfo-
rator is one of the most important factors contributing to-
wards varicose veins, the question of whether or not
perforator interruption can reduce varicosity recurrence is
still controversial.27e29 The REVAS (REcurrent Veins After
Surgery) study showed that recurrent varices were associ-
ated with perforators, neo-vascularity, and recurrent
saphenous insufﬁciency.9 The retrospective cohort study
from seven centers further conﬁrmed that perforating veins
were one of the four most important factors associated
with recurrent veins after saphenous vein thermal abla-
tion.30 However, opponents disagreed with perforator
interruption peremptorily at the time of GSV surgery as a
method to prevent recurrence.21 The reasons can be sum-
marized as follows. First, the treatment of GSV reﬂux alone
will concomitantly correct a signiﬁcant proportion of IPVs;
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techniques is associated with residual or “missed” IPVs;
ﬁnally, recurrence is frequently related to the progression of
chronic venous insufﬁciency, not just IPVs. Despite these
controversies, the results of the present study showed no
statistical difference in the recurrence rate of varicose veins
between the EVLA treated IPV group and the untreated IPV
group at either 6 or 12 months. A longer follow up period
may have provided clarity as to the fate of patients with IPV
EVLA and insight regarding varicose vein recurrence.
The current study has many limitations, the most
important being its single center retrospective design.
Although a signiﬁcant reduction of median ulcer healing
time was recorded in the EVLA treated IPV group, it cannot
be concluded, without a randomized control group, that the
additional IPV EVLA leads to better ulcer healing. Other
weaknesses include the lack of a quality of life instrument
and a short follow up period (12 months). Long-term follow
up is essential for the treatment of PVI as late recurrence is
well described.
In conclusion, from the currently available evidence it
seems that EVLA is safe and effective in ablating IPVs in
patients with PVI. However, at the 1 year follow up, the
addition of IPV EVLA had no effect on the ulcer healing rate,
VCSS, or varicose vein recurrence rate. Further prospective
randomized trials are required to deﬁne the long-term
beneﬁts of EVLA for IPVs.
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